These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 14608516

  • 1. Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
    Cohn JN.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):137-9. PubMed ID: 14608516
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Nov 16; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 5. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, Francis DP.
    Int J Cardiol; 2004 Feb 16; 93(2-3):105-11. PubMed ID: 14975535
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 16; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 16; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic management of heart failure: neurohormonal agents.
    Moser DK.
    Crit Care Nurs Clin North Am; 1993 Dec 16; 5(4):599-608. PubMed ID: 7905275
    [Abstract] [Full Text] [Related]

  • 9. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 10. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S, Kitakaze M.
    Nihon Rinsho; 2003 May 15; 61(5):821-6. PubMed ID: 12755009
    [Abstract] [Full Text] [Related]

  • 11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 15; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with ACE inhibitors and angiotensin-receptor blockers in heart failure.
    Scow DT, Smith EG, Shaughnessy AF.
    Am Fam Physician; 2003 Nov 01; 68(9):1795-8. PubMed ID: 14620599
    [Abstract] [Full Text] [Related]

  • 13. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, Murali S, Feldman AM, London B.
    J Am Coll Cardiol; 2004 Nov 16; 44(10):2019-26. PubMed ID: 15542286
    [Abstract] [Full Text] [Related]

  • 14. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 16; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 15. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 16; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 16. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 16; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 17. Managing the patient with diabetes mellitus and heart failure: issues and considerations.
    Fonarow GC.
    Am J Med; 2004 Mar 08; 116 Suppl 5A():76S-88S. PubMed ID: 15019865
    [Abstract] [Full Text] [Related]

  • 18. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P.
    Orv Hetil; 2005 May 01; 146(18):827-31. PubMed ID: 15926627
    [Abstract] [Full Text] [Related]

  • 19. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S.
    Kyobu Geka; 2007 Jun 01; 60(6):484-7. PubMed ID: 17564066
    [Abstract] [Full Text] [Related]

  • 20. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 01; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.